• BX Home
  • King Pharmaceuticals (KG): News

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

KING PHARMACEUTICALS (KG)

King Pharmaceuticals, Inc. is the world’s 39th-largest pharmaceutical company. It provides branded prescription pharmaceutical products worldwide It primarily offers branded prescription products for primary care physicians, neurologists, orthopedic surgeons, hospitals, internal medicine physicians, allergists, pediatricians, and pain specialists. Some brands include Altace for heart attack prevention; Levoxyl for hypothyroidism; Sonata for sleeping; and Skelaxin, a muscle relaxant.

King Pharmaceuticals (KG) is part of Business Exchange, suggested by Ginny Moore. This topic contains 133 news and 95 blog items. Read updated news, blogs, and resources about King Pharmaceuticals (KG). Find user-submitted articles and reactions on King Pharmaceuticals (KG) from like-minded professionals.

News

Please add new articles to this topic

Pfizer Profit Beats, but Revenue Misses Forecastsmore

the value of overseas sales, and for new products obtained in Pfizer's recent purchase of specialty drugmaker King...

Pfizer profits up 10 per centmore

the value of overseas sales, and for new products obtained in Pfizer's recent purchase of specialty firm King...

RPT-UPDATE 2-Pfizer drugs wilt, lower-margin units shinemore

the value of overseas sales, and for new products obtained in Pfizer's recent purchase of specialty drugmaker King...

Pfizer Profit Tops Forecast, but Revenue Falls Shortmore

the value of overseas sales, and for new products obtained in Pfizer's recent purchase of specialty drugmaker King...

Pfizer Profit Rises 10%more

at 60 cents. Revenue edged down 0.5% to $16.5 billion, with currency fluctuations and its recent King Pharmaceuticals...

UPDATE 6-Pfizer drug sales fall, lower-margin units shinemore

from a weaker dollar that boosted the value of sales abroad, new products obtained by the purchase of King...

Pfizer drug sales fall, lower-margin units shinemore

from a weaker dollar that boosted the value of sales abroad, new products obtained by the purchase of King...

Pfizer Posts 10% Profit Boostmore

in profit for its first quarter, helped by a lower tax rate and revenues from its acquisition of King Pharmaceuticals...

Pfizer, Parexel fall on sales reportsmore

Sales slipped to $16.5 billion from $16.6 billion, despite the inclusion of products from recently acquired King...

Pfizer 1Q profits rise 10% on lower costs, taxesmore

favorable currency exchange rates. First-quarter revenue got a boost of $224 million from sales of products made by...

Pfizer 1Q net up 10 percent on lower costs, taxesmore

favorable currency exchange rates. First-quarter revenue got a boost of $224 million from sales of products made by...

Market Forecast, May 3: What's on Tapmore

Tuesday is more likely to provide further insight into how well the integration of recent purchases Wyeth and King...

Pfizer profit top f'cast, revenue missesmore

the value of overseas sales, and for new products obtained in Pfizer's recent purchase of specialty drugmaker King...

Pfizer reports higher profit, but weak salesmore

Sales slipped to $16.5 billion from $16.6 billion, despite the inclusion of products from recently acquired King...

The Woman Pushing Pfizer To Break Upmore

"engaged in a continuous review of the role of each of our businesses.��� When Pfizer purchased generics maker...

Cephalon/Teva: Valient beats retreatmore

Extract not available.

Earnings Preview: Pfizer reports on first quartermore

Pfizer plans to use that to buy back stock and possibly make some deals.Last month, Pfizer bought King Pharmaceuticals...

Companies Attempt Abuse-Proof Pain Medsmore

expected to issue a decision about another oxycodone product -- Acurox, Pfizer's attempt (through the acquisition of...

On the Boardsmore

been appointed chairman. He replaces Yoav Z. Chelouch, who resigned. Markison is the former chairman and CEO of King...

DEALTALK-Buyers' stocks rewarded for good strategic dealsmore

recent examples of buyers' stocks rising on a deal announcement include Pfizer Inc's (PFE.N) purchase of King...

Rosetta Genomics Names Brian Markison Board Chairmanmore

Company's Board of Directors has appointed Director Brian A. Markison, former Chairman and Chief Executive Officer of...

DURECT Announces ELADUR�� (TRANSDUR��-Bupivacaine) Phase II Study Resu...more

ELADUR�� (TRANSDUR��-Bupivacaine), DURECT's proprietary investigational transdermal bupivacaine pain patch.

Pfizer selling Capsugel unit to KKR for $2.38Bmore

cutting research spending and eliminating thousands of jobs. In March it closed a $3.6 billion acquisition of King...

Pfizer Sells Capsugel Unit for $2.4 Billionmore

been adjusting its strategy accordingly. While the company recently completed its $3.6 billion deal for painkiller...

Pfizer recalls pain drug acquired in King dealmore

Just weeks after completing its $3.6 billion purchase of King Pharmaceuticals, Pfizer Inc (PFE.N) has recalled an...

Top Sources: King Pharmaceuticals (KG)

  • Reuters
  • MarketWatch
  • TheStreet.com
  • CNBC
  • Morningstar.com
  • BusinessWeek
  • Wall Street Journal Online
  • Smart Money
  • Motley Fool
  • Reuters UK

Most Active Users in this Topic

No user contributions

Featured White Papers

Post a Job

Jobs in this Topic

High Frequency Trader World Financial Desk | New York, NY
Posted: Feb 10
International Tour Director Kalos Golf | Chapel Hill, NC
Posted: Feb 8
Director of Grant Programs and Philanthropic Ventures Leadership Recruiters | Philadelphia, PA
Posted: Feb 7
Dean, Lee Business School University of Nevada, Las Vegas - Unlv | Las Vegas, NV
Posted: Feb 4
Loan Officer, Baton Rouge and Seedco Financial Services | New Orleans, LA
Posted: Feb 3

Report comment contains invalid characters. ()
cancel
Search Cancel